Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD MS, Theodore A Gooley, PhD, Kirsteen Maclean, PhD, Shamali Roy, PhD, Jesse Hubbard, Mario Marcondes, MD PhD, Beverly Torok-Storb, PhD, Tewari Muneesh, MD PhD

Blood (2015) 126 (23): 385.

https://doi.org/10.1182/blood.V126.23.385.385

Published: 2015

Journal Articles

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Eneida R. Nemecek, MD, Mohamed L. Sorror, MD, MS, Kristine C. Doney, MD, Bart Lee Scott, MD, Tibor J. Kovacsovics, MD, Richard Thomas Maziarz, MD, Ann E Woolfrey, MD, Jean Sanders, MD, Paul V. O’Donnell, Katherine Guthrie, PhD, H. Joachim Deeg, MD

Blood (2008) 112 (11): 2994.

https://doi.org/10.1182/blood.V112.11.2994.2994

Published: 2008

Journal Articles

Transfusion Requirements in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients Given Either Myeloablative or Nonmyeloablative Conditioning, and Effect of ABO Incompatibility on HCT Outcomes.

Zejing Wang, MD, PhD, Mohamed L. Sorror, MD, MS, Wendy Leisenring, Sc.D., Gary Schoch, David G. Malonely, MD, PhD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD

Blood (2008) 112 (11): 3268.

https://doi.org/10.1182/blood.V112.11.3268.3268

Published: 2008

Journal Articles

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 or 4 Gy) after Failure of First Allografts.

Boglarka Gyurkocza, MD, Thai M. Cao, MD, Rainer F. Storb, MD, Thoralf Lange, MD, Wendy Leisenring, Sc.D., Georg Franke, MD, Mohamed L. Sorror, MD, MS, David G. Maloney, MD, PhD, Judith Shizuru, MD, PhD, Brenda M. Sandmaier, MD

Blood (2008) 112 (11): 3272.

https://doi.org/10.1182/blood.V112.11.3272.3272

Published: 2008

Journal Articles

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, MD, MS, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Thomas Chauncey, MD, Richard T. Maziarz, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Dietger Niederwieser, MD, Edward Agura, MD, James C. Wade, MD, MPH, Amelia A Langston, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 2147.

https://doi.org/10.1182/blood.V112.11.2147.2147

Published: 2008

NARROW

Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT)

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Transfusion Requirements in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients Given Either Myeloablative or Nonmyeloablative Conditioning, and Effect of ABO Incompatibility on HCT Outcomes.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 or 4 Gy) after Failure of First Allografts.

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Email alerts

ASH Publications

American Society of Hematology

Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT)

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Transfusion Requirements in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients Given Either Myeloablative or Nonmyeloablative Conditioning, and Effect of ABO Incompatibility on HCT Outcomes.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 or 4 Gy) after Failure of First Allografts.

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only